The cell therapy processing market was valued at USD 1,723 million in 2019, and is projected to reach USD 12,132 million by 2027, registering a CAGR of 28.2% from 2020 to 2027.
Cell therapy processing refers to administration of living cells in a patient’s body for treating a disease. For cell processing therapy, different types of cells can be utilized, including neural cells, skeletal muscle cells, embryonic stem cells, hematopoietic stem cells, and mesenchymal cells. Moreover, it is used for the treatment of cancers, repairmen of spinal cord injuries, infectious & urinary diseases, autoimmune diseases, improvement of a weakened immune system, rebuilding damaged cartilage in joints, and helping patients with neurological disorders.
Increase in the demand for chimeric antigen receptor (CAR) T cell therapy, rise in the R&D for the advancement in the research associated with cell therapy, rise in the incidence of cardiovascular diseases, rise in the potential of cell therapies in the treatment of diseases associated with lungs using stem cell therapies, and increase in a number of clinical studies relating to the development of cell therapy processing are the major factors that drive the growth of the cell therapy processing market. In addition, introduction of novel technologies for cell therapy processing, large number of oncology-oriented cell-based therapy clinical trials, increase in adoption of regenerative drug, rise in government investments for cell-based research, and increase in number of GMP-certified production facilities across the globe are further expected to propel the growth of the cell therapy processing market. However, high-costs associated with the cell therapies, and bottlenecks experienced by manufacturers during commercialization of cell therapies are expected to hinder the growth of the market. Furthermore, the emerging economies present lucrative opportunities for the market.
Cell Therapy Processing Market Segmentation
The cell therapy processing market is segmented into offering type, application, and region. By type, the market is categorized into products, services, and software. The application covered in the segment include cardiovascular devices, bone repair, neurological disorders, skeletal muscle repair, cancer, and others. On the basis of region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, India, and rest of Asia-Pacific), and LAMEA (Latin America, Middle East, and Africa).
Segment review
Based on offering type, the market is categorized into products, services, and software. At present, products segment dominates the cell therapy processing market, and is anticipated to continue this trend over the forecast period. The key factors that driving the market growth are rise in the incidence of cardiovascular diseases, increase in demand for cell therapy processing, surge in adoption of allogeneic cell therapy, and introduction of novel technologies for cell therapy processing are majorly driving the growth of this segment. Some of the major market players that offer cell therapy processing products are BioTime, Inc., Regeneus Ltd., Targazyme, Inc., Bone Therapeutics, NeuroGeneration, and Invitrx Therapeutics, Inc.
Based on application, the market is classified into cardiovascular devices, bone repair, neurological disorders, skeletal muscle repair, cancer, and others. The skeletal muscle repair is the major shareholder in the global cell therapy processing market owing to rise in incidence of skeletal muscle injury, rise in geriatric population, increase in prevalence of chronic diseases, increase in usage of regenerative medicine, and increase in adoption of minimally invasive surgeries.
Snapshot of Asia-Pacific cell therapy processing market
Asia-Pacific presents lucrative opportunities for the key players operating in the cell therapy processing market, due to increase in patient awareness toward benefits offered by cell therapy processing, rise in number of hospitals equipped with advanced medical facilities, development of the R&D sector, rise in healthcare reforms, and technological advancements in cell therapy processing. The countries in this region are highly populated, with China being the first and India the second most populated countries. Therefore, the region possesses high growth potential owing to presence of huge patient base, which is expected to boost the growth of the Asia-Pacific cell therapy processing market. In addition, rise in demand for cell therapy processing, and presence of high population base incomes contribute toward the growth of the market. In addition, increase in research and development expenditure and surge in usage of cell therapy processing products augment the growth of the market. Furthermore, surge in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high market share is expected to drive the growth of the cell therapy processing market in the region.
The key players profiled in this report include Cell Therapies Pty Ltd, Invitrx Inc., Lonza Ltd, Merck & Co., Inc. (FloDesign Sonics), NantWorks, LLC, Neurogeneration, Inc., Novartis AG, Plasticell Ltd., Regeneus Ltd, and StemGenex, Inc.
Key Market Segments:
By Offering Type
By Application
By Region
Table of Content
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Market player positioning, 2018
3.3. Porter’s five force analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in the incidence of cardiovascular diseases
3.4.1.2. Rise in the demand for chimeric antigen receptor (CAR) t cell therapy
3.4.1.3. Increase in the development of stem cell therapy approaches
3.4.2. Restraint
3.4.2.1. Poor demand in under developed countries
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets
3.4.4. Impact analysis
CHAPTER 4: CELL THERAPY PROCESSING MARKET, BY OFFERING TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Products
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Services
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Software
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
CHAPTER 5: GLOBAL CELL THERAPY PROCESSING MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cardiovascular diseases
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Bone Repair
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Neurological Disorders
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Skeletal Muscle Repair
5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country
5.6. Cancer
5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country
5.7. Other Applications
5.7.1. Market size and forecast, by region
5.7.2. Market analysis, by country
CHAPTER 6: CELL THERAPY PROCESSING MARKET, BY REGION
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. North America CELL THERAPY PROCESSING market, by country
6.2.2.1. U.S.
6.2.2.1.1. U.S. market size and forecast, by offering type
6.2.2.1.2. U.S. market size and forecast, by application
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by OFFERING TYPE
6.2.2.2.2. Canada market size and forecast, by application
6.2.2.3. Mexico
6.2.2.3.1. Mexico market size and forecast, by OFFERING TYPE
6.2.2.3.2. Mexico market size and forecast, by application
6.2.3. North America market size and forecast, by offering type
6.2.4. North America market size and forecast, by application
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Europe cell therapy processing market, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by OFFERING TYPE
6.3.2.1.2. Germany market size and forecast, by application
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by OFFERING TYPE
6.3.2.2.2. France market size and forecast, by application
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by OFFERING TYPE
6.3.2.3.2. UK market size and forecast, by application
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by OFFERING TYPE
6.3.2.4.2. Italy market size and forecast, by application
6.3.2.5. Spain
6.3.2.5.1. Spain market size and forecast, by OFFERING TYPE
6.3.2.5.2. Spain market size and forecast, by application
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe market size and forecast, by OFFERING TYPE
6.3.2.6.2. Rest of Europe market size and forecast, by application
6.3.3. Europe market size and forecast, by OFFERING TYPE
6.3.4. Europe market size and forecast, by application
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Asia-Pacific CELL THERAPY PROCESSING market, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by offering type
6.4.2.1.2. Japan market size and forecast, by application
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by offering type
6.4.2.2.2. China market size and forecast, by application
6.4.2.3. India
6.4.2.3.1. India market size and forecast, by OFFERING TYPE
6.4.2.3.2. India market size and forecast, by application
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Rest of Asia-Pacific market size and forecast, by OFFERING TYPE
6.4.2.4.2. Rest of Asia-Pacific market size and forecast, by application
6.4.3. Asia-Pacific market size and forecast, by offering type
6.4.4. Asia-Pacific market size and forecast, by application
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. LAMEA CELL THERAPY PROCESSING market, by country
6.5.2.1. Latin America
6.5.2.1.1. Latin America market size and forecast, by OFFERING TYPE
6.5.2.1.2. Latin America market size and forecast, by application
6.5.2.2. Middle East
6.5.2.2.1. Middle East market size and forecast, by OFFERING TYPE
6.5.2.2.2. Middle East market size and forecast, by application
6.5.2.3. Africa
6.5.2.3.1. Africa market size and forecast, by offering type
6.5.2.3.2. Africa market size and forecast, by application
6.5.3. LAMEA market size and forecast, by OFFERING TYPE
6.5.4. LAMEA market size and forecast, by application
CHAPTER 7: COMPANY PROFILES
7.1. Cell Therapies Pty Ltd
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.2. INVITRX INC.
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.3. LONZA LTD
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. Merck & Co., Inc. (FloDesign Sonics)
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. NantWorks, LLC
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.6. Neurogeneration, Inc.
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.7. Novartis AG
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Plasticell Ltd.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Key strategic moves and developments
7.9. REGENEUS LTD
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. StemGenex, Inc.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers